Talent Pool

Contributed by:

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

Pharma POOL

Margaret M.FORAN
Pfizer Names Presidents for U.S., European Pharmaceuticals Businesses,Head of Corporate Affairs, and Corporate Secretary Pat Kelly and Ian Read have been appointed presidents responsible for the U.S. and European pharmaceuticals business es of Pfizer Inc., New York. Mr. Kelly, who joined Pfizer in 1981 and most recently served as senior VP of worldwide marketing, now serves as president of U.S. Pharmaceuticals. Mr. Kelly has held a number of marketing positions, including group VP for disease management, and is a member of the Pfizer Pharmaceuticals Group Leadership Team and the Pfizer Management Council. During his marketing career at Pfizer, Mr. Kelly has built and managed multidisci plinary teams that develop and implement educational and promotional programs in sup port of Pfizer medicines for cardiovascular, metabolic, infectious, neurologic, respiratory, inflammatory, and genitourinary disorders. Mr. Kelly was elected a VP of Pfizer in 1997. Mr. Read, who had served as senior VP of the Pfizer Pharmaceutical Group and executive VP of Europe and Canada, has been named president of Pfizer’s Europe and Cana da operations. Mr. Read joined Pfizer in 1978 and held a number of manage ment positions in Mexico, Ecuador, and Chile before being appointed country manager of Brazil. Before his appointment as executive VP for Europe and Canada in 2000, Mr. Read served as president of the Latin America region. Both he and Mr. Kelly report directly to Karen Katen, president of the global Pfizer Pharma ceuticals Group and executive VP, Pfizer. Separately, Chuck Hardwick has been named head of the company’s worldwide cor porate affairs division, and Margaret M. Foran was named corporate secretary. Mr. Hardwick succeeds Lou Clemente, who retired after 38 years with the company. Mr. Hardwick has been named senior VP, with global responsibility for government relations, media, philanthropy, and public policy, reporting to Hank McKinnell, chairman of the board and chief executive officer of Pfizer Inc. As president and executive director of the Pfizer Foundation, Mr. Hardwick is responsi ble for the company’s worldwide philanthropy programs and has led Pfizer’s initiatives to deliver medicines and medical support to HIV/AIDS communities around the world, particularly those in Africa. He joined Pfizer 36 years ago and also served as speaker of the New Jersey general assembly. In his new posi tion, he serves on the Pfizer Leadership Team, which consists of the company’s eight senior leaders. Ms. Foran, currently VP of corporate gov ernance, has been named secretary of Pfizer. An attorney who joined Pfizer in 1997, Ms. Foran most recently served as Pfizer’s assistant secretary and is responsible for having built a unique team focused exclusively on corporate governance and related issues. Ms. Foran is the former chair of the coordinating committee of the corporate governance task force of the business roundtable. Biotech POOL Christine CARBERRY James C. MULLEN James L. VINCENT Biogen Elects New Chairman and VP James L. Vincent is retiring as chairman and as a director of Biogen Inc., Cambridge, Mass. The board has elected as chairman James C. Mullen, who continues in his role as CEO. Mr. Mullen’s election as chairman completes a longstanding, planned transition under which Mr. Mullen succeeded Mr. Vincent as CEO in June 2000. Separately, Biogen has appointed Christine Car berry as VP, program and alliance management. Ms. Carberry oversees the biotechnology company’s development programs in the areas of autoimmune diseases, neurodegenera tion, oncology, and fibrosis. She also is respon sible for maintaining current and future busi ness partnerships in these areas. She reports to John Palmer, senior VP of corporate develop ment. Ms. Carberry joined Biogen in 1984 and held many positions in technical operations, including managing the startup of Biogen’s manufacturing facility in the Netherlands from 1999 to 2001. Most recently, she was the program execu tive of the LFA1 program, which is develop ing orally active smallmolecule antagonists that work to inhibit Tcell migration and acti vation that can lead to inflammatory diseases. Ms. Carberry holds a master of science in innovation and technology management from Boston University and a bachelor of science in biochemistry from the University of New Hampshire. TALENT POOL EXECUTIVE APPOINTMENTS AND PROMOTIONS IN THE HEALTHCARE INDUSTRY TALENT pool PharmaVOICE Dr. David M.SHLAES Idenix Selects Executive VP, R&D David M. Shlaes, M.D., Ph.D., joins Idenix Pharmaceuticals Inc., Cambridge, Mass., as executive VP of research and development. In his new role with Idenix, a biopharma ceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, Dr. Shlaes directs global research efforts in infec tious disease. Dr. Shlaes replaces Dr. Martin Bryant who passed away in March. Dr. Shlaes formerly was VP, infectious dis ease, with Wyeth Research, a division of Wyeth, and has an extensive background in the discovery and development of antibacteri al and antiviral compounds. Dr. Shlaes holds a Ph.D. in microbiology, a M.D. from Case Western Reserve, and a bach elor’s degree in biologychemistry from Lawrence University. Dr. Paul SPENCE Maxygen Appoints Senior VP Maxygen Inc. has named Paul Spence, D.Phil., to the position of senior VP, research and development, leading the human therapeutics product discovery and development programs. Dr. Spence joins Maxygen, located in Redwood City, Calif., from Pharmacia Corp. where he was VP of biotechnolo gy and a member of the Pharmacia Research Leadership Team that was responsible for managing all of Pharma cia’s research projects. He received his D.Phil. in molecular virology from Oxford University. Specialty POOL Dr.William BAKER Corus Pharma NamesVP, Research Corus Pharma, a Seattlebased biotech and specialty pharmaceutical development company, has named William Baker, Ph.D., as VP of research. Dr. Baker has more than 20 years experience and is responsible for developing the company’s pipeline of products. Previously, Dr. Baker was chief oper ating officer and VP of research for Optimer Pharmaceuticals Inc.Dr. Baker earned a Ph.D. in organic chem istry from the University of Illinois, Champaign, and a B.S. in chemistry from the University of Washington. Scott BREAKSTONE Cindy WILLIAMS Dr. H. Jurgen van den WOLDENBERG Bradley Pharmaceuticals Adds Three New Executives to Senior Management Bradley Pharmaceuticals Inc. has added three new members to its senior management team. Dr. H. Jurgen van den Woldenberg has joined the company as executive VP, general manager, of the Kenwood Therapeutics divi sion, Cindy Williams has been added as VP of creative services, and Scott Breakstone has joined the company as director of managed care. Dr. Woldenberg has more than a decade of global and domestic leadership in the phar maceutical industry. Before joining Fairfield, N.J.based Bradley, Dr. Woldenberg founded Direct Consulting, where he provided process improvement and process reengineering to both pharmaceutical and biotech companies. Ms. Williams brings more than 12 years of pharmaceutical marketing experience to Bradley Pharmaceuticals. Most recently, Ms. Williams served as senior VP at International Meetings and Science, where she led the team for the prelaunch communication and mar keting for a new cardiovascular drug from Merck/ScheringPlough. Mr. Breakstone brings more than 20 years experience in the areas of health and managed care. Most recently, Mr. Breakstone was an independent healthcare consultant. Dr. Heinrich GUGGER Paradigm Genetics Appoints President and CEO Paradigm Genetics Inc. has appointed Heinrich Gugger, Ph.D., as president and Graham LEWIS Representatives from the Pharmaceutical Busi ness Intelligence and Research Group (PBIRG) and the pharmaceutical industry have selected Graham Lewis, VP of IMS Consulting, as the first recipient of the Mary Clement Lifetime Achieve ment Award. PBIRG is a nonprofit industry association dedicated to the advancement of global health care marketing research, business intelligence, and strategic planning in theory and practice. The award will be issued periodically to recognize outstanding lifetime contributions to the phar maceutical industry and the market research pro fession. To be considered, nominees must demonstrate outstanding character and ethics; dedication to their companies, colleagues, and PBIRG; superior expertise in developing and executing market research, business intelligence projects, and methodologies; and dedication to the betterment of the market research profession. The award, named in honor of researcher Mary Clement, a respected PBIRG member who died of cancer last year, was presented to Mr. Lewis by Nancy Wilkerson, PBIRG VP of programs and education at the agen cy’s annual conference in San Antonio, Texas. “We are very pleased that Graham Lewis has been selected as the first recipient of this award,” says Kathryn Jones, Wyeth executive and president of PBIRG. “His market research expertise, creativity, and dedication to training and mentoring colleagues in this profession have been extraordinary. His selection is truly a tribute to Mary Clement, who displayed the very same commitment to the market research profession.” Mr. Lewis worked for major international companies such as Philips and Cadbury Schweppes before joining the pharmaceutical industry with Eli Lilly in 1971. In 1973, he joined Medical Market Studies and became managing director in 1978. Medical Market Studies merged into the IMS Pharma Strategy group in 1992. In April , he was named VP of the IMS Europe Pharma Strategy group. IMS CONSULTING EXECUTIVE RECEIVES LIFETIME ACHIEVEMENT AWARD FOR MARKET RESEARCH EXCELLENCE Graham Lewis is the inaugural recipient of the Mary Clement Lifetime Achievement Award. Graham Lewis is the inaugural recipient of the Mary Clement Lifetime Achievement Award. TALENT pool PharmaVOICE CEO. John Hamer, Ph.D., former interim president and CEO, con tinues to serve as the com pany’s chief scientific offi cer. Paradigm Genetics, Research Triangle Park, N.C., is a lifesciences company using genomics and metabolomicsbased technologies to speed the discovery of products for agriculture and human health. Dr. Gugger, 51, brings to Paradigm exten sive business and scientific industry experi ence. Most recently, Dr. Gugger served as the first president of Syngenta Crop Protection Inc. where he led the merger integration between Novartis Crop Protection and Zeneca Agrochemicals. Dr. Gugger holds a Ph.D. in inorganic and physical chemistry from the University of Bern. Genomics POOL Roberto CETRULLO Human Genome Sciences Appoints VP, Business Development Roberto Cetrullo has joined Human Genome Sciences Inc. as VP of business devel opment. Mr. Cetrullo brings more than 15 years of pharmaceutical industry experience to Human Genome Sciences. Most recently, Mr. Cetrullo was VP of business developmentU.S. Medicines Group, at BristolMyers Squibb Co., where he was responsible for leading major U.S. pharmaceutical business develop ment activities. Mr. Cetrullo reports to Ellen S. Baron, Ph.D., senior VP of business devel opment. Mr. Cetrullo received his master of business administration degree in finance and interna tional business from The Wharton School of Business in Philadelphia and a doctorate in food sciences summa cum laude from the Uni versity of Bologna, Bologna, Italy. Kevin CORCORAN Dr.Thomas J. VASICEK Lynx Therapeutics Fortifies Senior Management Team Kevin Corcoran has been promoted to pres ident and CEO of Lynx Therapeutics Inc., Hayward, Calif. Mr. Corcoran has served as medicine through the application of popula tion genomics and informatics, has announced two promotions. Kevin Rakin, president of Genaissance Pharmaceuticals, has assumed the newly created position of chief operating officer, and Joseph Keyes has been promoted to VP and chief financial officer. Mr. Rakin previously held the position of chief financial officer. Mr. Rakin, 41, has been responsible for the company’s financing, business development activities, and investor relations. Mr. Rakin’s new position reflects the importance that Genaissance is placing on executing its busi ness plan of establishing additional corporate collaborations, and forming joint ventures and marketing alliances to generate a balanced portfolio of royaltybearing agreements for pharmaceutical products. Mr. Keyes, 44, joined Genaissance, located in New Haven, Conn., in March 2001 as exec utive director of finance. Mr. Keyes is a certi fied public accountant and brings to Genais sance more than 20 years of financial experience. Before joining Genaissance, Mr. Keyes was VP of finance for DSL.net Inc. Lee R. MCCRACKEN Dr. Gary WOODNUTT Diversa Announces Key Pharmaceutical Management Appointments Diversa Corp., a leader in applying proprietary genomic technologies for the rapid discovery and optimization of novel products from genes and gene pathway, has announced two key phar maceutical management appointments. Gary Woodnutt, Ph.D., has been appoint ed senior VP of pharma ceutical R&D, and Lee R. McCracken has been appointed senior VP of pharmaceutical business development. These additions to Diversa’s senior man agement are expected to increase the strength and commercial experience of Diversa’s phar maceutical group. Dr. Woodnutt joins San Diegobased Diversa from GlaxoSmithKline with more than 20 years of experience in the pharmaceu tical industry. As VP of microbiology at GSK, he was responsible for all aspects of antibacte rial drug discovery and played a key role in the development and launch of a number of suc Lynx’s VP of operations for the last three years. He has been instrumental in developing and advancing existing commercial relationships and in establishing new commercial arrange ments. Mr. Corcoran also was a member of the original development team for Lynx’s Massive ly Parallel Signature Sequencing technology and has led Lynx’s development of its nextgen eration MPSS instruments. Mr. Corcoran succeeds Norrie Russell, Ph.D., who resigned his position as Lynx’s president and CEO to pursue other interests. Mr. Corcoran, who has been with Lynx for seven years, has 20 years of informatics and bioinstrumentation experience. Lynx also has announced the addition of Thomas J. Vasicek, Ph.D., as VP, business development. Dr. Vasicek joins Lynx as a member of the senior management team and leads the business development efforts for MPSS and Protein ProFiler. Dr. Vasicek brings to Lynx considerable technical and business expertise in the field of gene expres sion analysis. Dr. Vasicek, who studied chemistry and molecular biology, received a bachelor’s degree at the Massachusetts Institute of Technology, has a doctorate degree from Harvard Medical School, and a postdoctoral degree from Prince ton University. Nina V. GILES Hyseq NamesVP,Business Development In her new position as VP of business develop ment, Nina V. Giles leads the business development efforts of Hyseq Pharma ceuticals Inc., Sunnyvale, Calif. Ms. Giles joins Hyseq from Incyte Genomics Inc. where she held various positions in the commercial organization from 1997 to 2002; most recently serving as VP, business develop ment, where she was a leading contributor to Incyte’s revenue generation. Ms. Giles received her bachelor’s degree from the University of California at Davis. Joseph KEYES Kevin RAKIN Genaissance Management Appointments Reflect Focus on Commercialization Genaissance Pharmaceuticals Inc., which is establishing the new field of personalized TALENT pool PharmaVOICE Discovery POOL Taylor J. CROUCH Discovery Partners International Appoints President and Chief Operating Officer Discovery Partners International Inc., San Diego, has named Taylor J. Crouch president and chief operating officer. Mr. Crouch brings to the com pany more than 20 years of experience in the phar maceutical industry and is responsible for the management of all of Dis covery Partners’ operating activities. Mr. Crouch previously was president and CEO of Variagenics Inc. Mr. Crouch received his B.S. in chemical engineering, cum laude, from Princeton Uni versity and his MBA in international finance and marketing from the University of Chicago. Dr. Jennifer A. FILBEY Nobex Announces Executive Promotion Jennifer A. Filbey, Ph.D., has been promot ed to VP of business and market development Device/Diagnostics POOL Bill ELLIOTT Executive VP Position Created at Quidel Bill Elliott has joined Quidel Corp., a provider of rapid pointofcare diagnostic tests, in the newly created, officerlevel posi tion of executive VP. In this role, Mr. Elliott is responsible on a global scale for Quidel’s sales, marketing, medical affairs, and strategic planning and business development activities. Mr. Elliott brings to Quidel, San Diego, more than 25 years of healthcarerelated senior management experience. Before joining Quidel, Mr. Elliott was chairman, president, and CEO of Embion Inc. Dr. James GODSEY GenProbe Expands Team James Godsey, Ph.D., has joined GenProbe Inc. as executive VP, develop ment, reporting to Henry L. Nordhoff, president and CEO. Dr. Godsey has more than 25 years experience in the diagnostics indus try, spanning both large and small companies. He comes to the San Diegobased diagnostics company from ThermoGenesis Corp., where he was president and chief operating officer. Thomas J. HOOK CTI Molecular Imaging Fills Executive Position CTI Molecular Imaging Inc., a provider of positron emission tomography and molecular imaging equipment, radiopharmaceuticals, and services based in Knoxville, Tenn., has selected Thomas J. Hook as president of CTI Services Inc. and senior VP of CTI Molecular Imaging Inc. Educated and trained as an analytical chemist, Mr. Hook most recently held the position of general manager, global function al and molecular imaging, for GE Medical Systems. With more than 15 years of business man agement and military experience, Mr. Hook has held a number of positions of increasing responsibility. Mr. Hook received his bachelor’s degree in chemistry and mathematics from St. Bonaven ture University, a master’s degree in chemistry from SUNY, Buffalo, and his MBA from Van derbilt University. He served seven years in the Navy where he completed his nuclear engineering training at the Navy Nuclear Power School. cessful antibiotics, including Augmentin, Timentin, and Bactroban. Dr. Woodnutt received his B.S. in bio chemistry and physiology at the University of Leeds and his Ph.D. in biochemistry and phys iology from the University of Reading. Before joining Diversa, Mr. McCracken was president and chief business officer of GenStar Therapeutics Corp. Mr. McCracken holds a B.S. in commerce from Santa Clara University, a M.S. in com puter science from the University of Dayton, and a masters in business administration from The Anderson School at UCLA. Dr.Trevor J. NICHOLLS Affymetrix Creates Position of Chief Commercial Officer, Global Operations Dr. Trevor J. Nicholls, D.Phil., has been appointed to the newly created position of chief commercial officer, global operations, at Affymetrix Inc. In this position, Dr. Nicholls is responsible for leading the company’s glob al sales, marketing, and manufacturing opera tions. In his new position, Dr. Nicholls reports directly to Susan E. Siegel, president of Affymetrix. Before joining Affymetrix, which is based in Santa Clara, Calif., Dr. Nicholls was founder and CEO of Oxagen Ltd. Dr. Nicholls earned his B.S. and a D.Phil. in biochemistry from the University of York. at Nobex Corp., a drugdelivery company spe cializing in medicinal chemistry applied to optimizing the delivery of therapeutic drugs. Dr. Filbey joined Nobex, Research Triangle Park, N.C., in 1999 as executive director of business and market development and has been the key contributor to the company’s growth through identifying and closing business agree ments with pharmaceutical and biotechnology companies that leverage Nobex technology. Before joining Nobex, Dr. Filbey led a pro tein drug delivery group for Aventis Research and Technology in Frankfurt, Germany. Dr. Filbey earned her Ph.D. in physical chemistry at Virginia Polytechnic Institute in Blacksburg, Va., and did postdoctorate work at the CNRS, Centre National de la Recherche Scientifique, in Mulhouse, France. Emerging POOL Jim NEAL Iconix Appoints CEO Iconix Pharmaceuticals Inc., a chemoge nomics company based in Mountain View, Calif., has appointed Jim Neal as CEO. Mr. Neal, who was previously executive VP of sales, marketing, and business development for Incyte Genomics, succeeds Keith Bostian, Iconix’s founder. Mr. Neal completed his B.Sc. in biology TALENT pool PharmaVOICE and his M.Sc. in genetics and plant breeding at the University of Manitoba in Canada. He also holds an executive MBA from Washing ton University. Joe SCHMIDT Dr. David STALKER Ventria Bioscience Adds TwoVPs to Management Team David Stalker, Ph.D., and Joe Schmidt have been added to Ventria Bioscience’s man agement team to advance its product commer cialization plans. Ventria Bioscience, located in Sacramento, Calif., is a developmentstage biotechnology company engaged in the pro duction of recombinant proteins that have applications in human and animal health. Dr. Stalker is responsible for corporate development and for overseeing Ventria Bio science’s intellectual property, technology licensing, and bloodprotein product manage ment activities. He received his Ph.D. in cell biology and biochemistry from the University of Cincin nati. In addition, Dr. Stalker was a postdoctor al fellow at the University of California, San Diego. Before coming to Ventria Bioscience, Dr. Stalker held several leadership positions at Calgene. Mr. Schmidt leads Ventria Bioscience’s business development efforts, including responsibility for the commercialization of the company’s lead products, Lactoferrin and Lysozyme. He will work with Ventria’s collab orators to successfully launch these products in human health and animal health. Mr. Schmidt has a MBA from The Univer sity of Chicago and a B.A. in finance from Wartburg College. Before joining Ventria Bioscience, Mr. Schmidt was involved in business develop ment, new product development, and finance at CyberCrop, Koch Industries, and Cargill. Supplier POOL Patrick G. CHASSAIGNE PHT Appoints Executive VP of Global Sales, Marketing,and Strategic Alliances PHT Corp., a provider of mobile and Webbased solutions for the electron ic collection and manage ment of clinical data, has tapped Patrick G. Chas saigne as executive VP of global sales, marketing, and strategic alliances. Mr. Chassaigne is based in PHT’s headquarters in Charlestown, Mass. Before joining PHT, Mr. Chassaigne was director of lifesciences solutions at Compaq Computer Corp. John COLAIACOVO Quovadx Appoints Senior VP of North American Healthcare Sales John Colaiacovo, newly appointed senior VP of North American health care sales, brings 25 years of healthcare sales man agement experience to Quovadx Inc., a provider of total business integra tion software and services. Before joining Quovadx, Englewood, Colo., Mr. Colaiacovo was director of western region al sales at Oracle Corp. He holds a MHA from Ohio State University and a B.S. from West Liberty State College. Jan FULTON Dr. Bruce MALOFF CBTechnologies Announces Executive Hires CB Technologies Inc., a clinicaltrials tech nology company, has appointed Bruce Maloff, Ph.D., to the newly created position of chief clinical officer and Jan Fulton as senior VP of product development. Before joining Exton, Pa.based CB, Dr. Maloff was chief business officer for First Genetic Trust. Dr. Maloff is an honors graduate with a bachelor of science degree in biology from Syracuse University and a Ph.D. in cellular physiology from The University at Albany. As senior VP of product development, Ms. Fulton oversees the continued development of CB’s MetaTrial clinical electronic datacapture software, managing the product development teams, product testing teams, and product extension teams. Most recently, Ms. Fulton held the chief operating officer position at CyberShift Inc. Ms. Fulton is a Phi Beta Kappa graduate of the University of North Carolina at Chapel Hill. Dr. Ihor GUSSAK Former Aventis Director Joins eResearchTechnology With more than 20 years of cardiology experience, Ihor Gussak, M.D., Ph.D., FACC, joins Philadelphiabased eResearchTechnolo gy Inc. from Aventis Pharmaceuticals, where he served as associate global clinical director, cardiovascular global product realization. In addition to defining ECG analysis results for cardiac safety implications, Dr. Gussak will consult with eResearchTechnology’s major pharmaceutical clients on cardiac safety determina tion and use of the compa ny’s services and products during the protocol design process. He also is responsible for developing the ongoing strategy for eResearchTechnology’s cardiac safety services and supporting technol ogy, which will be driven through his forma tion and management of eResearchTechnolo gy’s medical advisory council. Fred NAZEM New Round of Financing Leads to Change at Top for Araccel In connection with a recapitalization plan, Fred Nazem of Nazem & Co. has become chairman of Horsham, Pa.based Araccel Corp., a provider of validated, innovative, and proven eclinical solutions that capture, maintain, analyze, distribute, manage, and report clinicaltrial data. “I am delighted to lead this investment in Araccel with the executive management team,” Mr. Nazem says. “Pharmaceutical R&D must fundamentally change because of the discovery of the human genome. We are witnessing the dawning of a new age of drug discovery, longevity, and disease management where the need for clinical trials will increase by an order of magnitude. Araccel manage ment’s participation in the financing shows their faith in the extraordinary potential for eClinical Solutions to fundamentally change the way drugs are developed. As chairman, I look forward to growing Araccel into the pre miere company in electronic clinical trials.” TALENT pool PharmaVOICE Dr. Stuart PORTNOY PharmaNet Adds Former FDA Branch Chief to Staff PharmaNet Inc., an international drug development company, has tapped Stuart Portnoy, M.D., as director of medical device consulting. Dr. Portnoy was most recently a branch chief and acting deputy director in the Center for Devices and Radiologic Health at the U.S. Food and Drug Administration. Dr. Portnoy received his M.D. from George Washington University School of Medicine. He also holds a master of science degree in bio engineering from the University of Pennsylva nia and a bachelor of science degree in chemi cal engineering from Tufts University. Dr. Portnoy is based in the Washington, D.C. office. Service POOL Lydia ADAMS Rona MCGREEVY Physicians Interactive Names NewDirector and Managing Editor Physicians Interactive, a provider of interactive healthcare product pro motion and education solutions for physicians and healthcare profession als, has appointed Rona McGreevy as the compa ny’s director of content and compliance and Lydia Adams as manag ing medical editor. Most recently, Ms. McGreevy held a posi tion in global medical marketing at Baxter International. Ms. Adams joins the Libertyville, Ill.based company from Discovery International where she served as associate managing medical editor. Patrick BLAIR DeLor appoints Marketing VP DeLor, a brand identi ty consultancy, has pro moted Patrick Blair to VP of marketing, from director of marketing. Mr. Blair leads the firm’s pharmaceutical business unit. As a brand consultant for DeLor, Mr. Blair has worked in develop ment of product brand revitalizations and integrated communications programs. Ora GUY Sherrydean HILL Kimbre JORDANHEGAMIN Zachary LENTZ S.G.Madison Announces New Hires S.G. Madison, Irving, Texas, a fullservice medi cal education and market ing subsidiary of inChord Communications Inc., has announced the hire of sev eral new employees: Ora Guy, Sherrydean Hill, Kimbre JordanHegamin, and Zachary Lentz. Ms. Guy has been named communications department coordinator. She is responsible for online registration and documentation for S.G. Madison and The Center for Biomedical Continu ing Education meetings, including honoraria and expense tracking. Previ ously, Ms. Guy was media secretary/assistant for Temerlin McClain. Ms. Hill has been named communication/ database coordinator. Before joining the company, she was project coordinator at Sprint PSC. Ms. JordanHegamin has been named speak er corps manager. Her responsibilities include planning and coordinating meetings and engagements for physicians. Previously, she was VP of corporate events for One World Events. Mr. Lentz has been named account execu tive. Previously, he worked as publications mar keting manager at Physician’s Education Resource/Cancer Information Group in Dallas. Kim MCANDREWS Medicalliance Appoints Account Manager Medicalliance Inc., a medical education agency located in Columbia, Md., has appointed Kim McAn drews as an account man ager. Before joining Medi calliance, Ms. McAn drews was a public rela tions account manager for a fullservice marketing communications agency where she was involved in project manage ment, media relations, product launches, event planning, and advertising. Medicalliance helps clients enhance market positioning and alignment or realignment of pharmaceutical and managedcare products at any stage of their life cycle. Diane SHAMY ClinPhone Expands Project Team ClinPhone Inc. has appointed Diane Shamy to its clinical project team as the company continues to build its U.S. opera tion, which is based in Princeton, N.J. The clini caltrial management company’s headquarters are based in Nottingham, U.K. As a clinical project coordinator, Ms. Shamy is responsible for working with both sponsor pharmaceutical companies and ClinPhone’s internal operations team to ensure all IVR requirements of sponsor protocols are met. Ms. Shamy has an extensive background in project management and laboratory opera tions, training, and investigator presentations. She brings more than five years of experience in laboratory procedures and project manage ment as well as two years as a clinical trials project manager with LabCorp. Lee SHAPIRO Allscripts Appoints President Allscripts Healthcare Solutions, Libertyville, Ill., a provider of pointofcare decision support tools for physicians, has announced that Lee Shapiro has been promoted to president. Glen Tullman contin ues in his role as chairman and CEO. Most recently, Mr. Shapiro, who has been with the company for two years, was executive VP, business development. Mr. Shapiro is a graduate of The Law School at The University of Chicago. TALENT pool PharmaVOICE Media POOL Dr. Anthony N. DEMARIA Editor in Chief Named for the Journal of the American College of Cardiology Anthony N. DeMaria, M.D., vice chair man of medicine at the University of Califor niaSan Diego and a cardiologist recognized for his clinical, academic, and leadership expe rience in the field, has been named editor in chief of the Journal of the American College of Cardiology. JACC is the nation’s leading source of clinical information on cardiology for healthcare professionals. Dr. DeMaria has been active in the three basic areas of academic medicine — investiga tor, teacher, and clinician. He also has consid erable administrative experience, serving as chief of the cardiology division at two institu tions over a 19year period. At the University of CaliforniaSan Diego, where he has been the division chief for nine years, he also has been the vice chairman of medicine until resigning to become editor of JACC. In addition, he has served as the pres ident of both the American College of Cardi ology and the American Society of Echocar diography. Dr. DeMaria takes over as editor of JACC following the 10year tenure of Dr. William Parmley. Agency POOL Daniel ARENHOLM Ribotsky Worldwide names VP and General Manager Daniel Arenholm has been named VP and general manager of the healthcare communica tions agency, Ribotsky Worldwide, located in Somerset, N.J. Previously, Mr. Aren holm held a position at Publicis MSW in France. Mr. Arenholm, a native of Sweden, also managed worldwide communi cations projects including, Ericsson world wide, Galderma, SchlumbergerSema, and SVT, the Swedish Television Network. Rita BRETT AdairGreene Selects Industry Veteran as Senior VP and Creative Director Rita Brett, a 20year industry veteran, has been named senior VP and cre ative director at Atlanta based AdairGreene Healthcare Communica tions, a fullservice mar keting communications agency, and division of AdairGreene Inc., which in turn is a division of McCannErickson WorldGroup. Ms. Brett has assumed overall responsibili ty for the creative department and reports directly to Rich Levy, president and chief oper ating officer of AdairGreene. Ms. Brett previously was VP at Lally McFarland & Pantello, where she served as art/creative director on a number of accounts. She was instrumental in assisting with the global launch of Bextra, a Cox2 inhibitor being marketed by Pfizer Inc. and Pharmacia Corp. A graduate of Hampshire College in Amherst, Mass., Ms. Brett studied advertising and design at the School of Visual Arts. She has won awards from the Rx Club, the Art Director’s Club, and the Advertising Club of New York. Jo Ann CAMPBELL Julia FARALDO Lori MATHEWS Johanna OSBORNE Laura SCHUTZE Jody WILK CommonHealth Agencies Announce Hires and Promotions Three CommonHealth companies have added new staff members to strengthen their teams. CommonHealth, a global healthcare communications network, is a WPP Group company. ProCom International, CommonHeath’s medi caleducation company, has announced the addi tion of Jo Ann Campbell and Johanna Osborne to its team. Ms. Osborne has been named VP, professional relations. In her new position, Ms. Osborne plays a role in direct ing strategic medicaleducation programs supporting her assigned accounts. In addition, she works to secure new busi ness opportunities for the company. Before joining ProCom, Ms. Osborne was VP, busi ness development, with University Research Associates Rx. Ms. Campbell has joined ProCom Interna tional, CommonHealth’s medical education division, as an associate program manager. She is responsible for the implementation of medicaleducation pro grams in congruence with her clients’ marketing objectives. Ms. Campbell formerly was an associate project director with Hyphen. Thomas Ferguson Associates, Common Health’s founding professional advertising and promotions unit, has announced three accountrelated promotions. At the agency, Julia Faraldo has been pro moted to account executive from assistant account executive. Lori Mathews has been named account supervisor at Thomas Ferguson from senior account executive. Ms. Mathews’ responsibili ties include strategic consulting and new product concept development. In other Thomas Ferguson news, Jody Wilk has been promoted to account supervisor from senior account executive. In her expand ed position, Ms. Wilk manages the overall daily business activities and remains responsi ble for both strategic and tactical activities on her assigned accounts. The Quantum Group, a CommonHealth con sumer advertising and promotions company, has strengthened its account services team through the addition of Laura Schutze, who joins the agency as an account supervisor. Please send your personnel announcements to feedback@pharmalinx.com. Pardon us … In the July/August issue of Pharma VOICE, Advanced Clinical Communi cations Inc. was listed as being in New Hope, Pa., the company is located at River Walk, 201 S. Main St., Lam bertville, N.J. 08530; phone (609) 3974100. PharmaVOICE apologizes for the error.

Posted in:

Post a Comment

You must be logged in to post a Comment.